Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
Nanobiotix has announced the upcoming presentation of complete results from their Phase 1 study of JNJ-1900 (NBTXR3) in pancreatic cancer patients. The presentation will take place at ESTRO 2025 on May 4th at 11:00 AM EDT, delivered by Principal Investigator Dr. Eugene Koay.
The study focused on patients with locally advanced or borderline resectable pancreatic cancer, conducted at The University of Texas MD Anderson Cancer Center. Following the presentation, Nanobiotix will host a conference call on May 5th at 8:00 AM EDT, featuring CEO Laurent Levy to discuss the findings.
The company, listed on both Euronext (NANO) and NASDAQ (NBTX), is advancing their nanoparticle-based therapeutic approach to expand cancer treatment options. Participants can join the discussion through either a webcast or audio-only option, with the opportunity to submit questions in advance to investors@nanobiotix.com.
Nanobiotix ha annunciato la prossima presentazione dei risultati completi del loro studio di Fase 1 su JNJ-1900 (NBTXR3) nei pazienti affetti da cancro al pancreas. La presentazione avverrà durante ESTRO 2025 il 4 maggio alle 11:00 EDT, a cura del ricercatore principale, il dott. Eugene Koay.
Lo studio ha coinvolto pazienti con cancro al pancreas localmente avanzato o borderline resecabile, condotto presso l'Università del Texas MD Anderson Cancer Center. Dopo la presentazione, Nanobiotix terrà una conference call il 5 maggio alle 8:00 EDT, con la partecipazione del CEO Laurent Levy per discutere i risultati.
L'azienda, quotata sia su Euronext (NANO) che su NASDAQ (NBTX), sta portando avanti il suo approccio terapeutico basato su nanoparticelle per ampliare le opzioni di trattamento del cancro. I partecipanti potranno seguire la discussione tramite webcast o audio, con la possibilità di inviare domande in anticipo all'indirizzo investors@nanobiotix.com.
Nanobiotix ha anunciado la próxima presentación de los resultados completos de su estudio de Fase 1 sobre JNJ-1900 (NBTXR3) en pacientes con cáncer de páncreas. La presentación se realizará en ESTRO 2025 el 4 de mayo a las 11:00 AM EDT, a cargo del investigador principal, el Dr. Eugene Koay.
El estudio se centró en pacientes con cáncer de páncreas localmente avanzado o borderline resecable, llevado a cabo en la Universidad de Texas MD Anderson Cancer Center. Tras la presentación, Nanobiotix organizará una conferencia telefónica el 5 de mayo a las 8:00 AM EDT, con la participación del CEO Laurent Levy para discutir los hallazgos.
La empresa, cotizada en Euronext (NANO) y NASDAQ (NBTX), está avanzando en su enfoque terapéutico basado en nanopartículas para ampliar las opciones de tratamiento del cáncer. Los participantes podrán unirse a la discusión mediante webcast o solo audio, con la posibilidad de enviar preguntas por adelantado a investors@nanobiotix.com.
Nanobiotix는 췌장암 환자를 대상으로 한 JNJ-1900 (NBTXR3) 1상 연구의 완전한 결과를 곧 발표할 예정이라고 밝혔습니다. 발표는 ESTRO 2025에서 5월 4일 오전 11시(EDT)에 책임 연구원인 Dr. Eugene Koay가 진행합니다.
이 연구는 텍사스 대학교 MD Anderson 암센터에서 국소 진행성 또는 경계선 절제 가능한 췌장암 환자를 대상으로 수행되었습니다. 발표 후 Nanobiotix는 5월 5일 오전 8시(EDT)에 CEO Laurent Levy가 결과를 논의하는 컨퍼런스 콜을 개최할 예정입니다.
유로넥스트(NANO)와 나스닥(NBTX)에 상장된 이 회사는 나노입자 기반 치료법을 발전시켜 암 치료 옵션을 확대하고 있습니다. 참가자들은 웹캐스트 또는 오디오 전용 옵션을 통해 토론에 참여할 수 있으며, 사전에 investors@nanobiotix.com으로 질문을 제출할 수 있습니다.
Nanobiotix a annoncé la prochaine présentation des résultats complets de leur étude de phase 1 sur JNJ-1900 (NBTXR3) chez des patients atteints de cancer du pancréas. La présentation aura lieu lors de ESTRO 2025 le 4 mai à 11h00 EDT, présentée par le chercheur principal, le Dr Eugene Koay.
L'étude portait sur des patients atteints d'un cancer du pancréas localement avancé ou borderline résécable, menée à l'Université du Texas MD Anderson Cancer Center. Après la présentation, Nanobiotix organisera une conférence téléphonique le 5 mai à 8h00 EDT, animée par le PDG Laurent Levy pour discuter des résultats.
L'entreprise, cotée à la fois sur Euronext (NANO) et NASDAQ (NBTX), fait progresser son approche thérapeutique basée sur les nanoparticules pour élargir les options de traitement du cancer. Les participants pourront suivre la discussion via un webcast ou en audio uniquement, avec la possibilité de soumettre des questions à l'avance à investors@nanobiotix.com.
Nanobiotix hat die bevorstehende Präsentation der vollständigen Ergebnisse ihrer Phase-1-Studie zu JNJ-1900 (NBTXR3) bei Patienten mit Bauchspeicheldrüsenkrebs angekündigt. Die Präsentation findet auf der ESTRO 2025 am 4. Mai um 11:00 Uhr EDT statt und wird vom leitenden Forscher Dr. Eugene Koay gehalten.
Die Studie konzentrierte sich auf Patienten mit lokal fortgeschrittenem oder grenzwertig resezierbarem Bauchspeicheldrüsenkrebs und wurde am University of Texas MD Anderson Cancer Center durchgeführt. Nach der Präsentation veranstaltet Nanobiotix am 5. Mai um 8:00 Uhr EDT eine Telefonkonferenz, bei der CEO Laurent Levy die Ergebnisse erläutern wird.
Das Unternehmen, das an der Euronext (NANO) und der NASDAQ (NBTX) gelistet ist, verfolgt einen therapeutischen Ansatz auf Nanopartikelbasis, um die Behandlungsmöglichkeiten bei Krebs zu erweitern. Teilnehmer können der Diskussion per Webcast oder nur Audio folgen und haben die Möglichkeit, im Voraus Fragen an investors@nanobiotix.com zu senden.
- Phase 1 study for pancreatic cancer treatment JNJ-1900 (NBTXR3) completed both dose escalation and expansion parts
- Study conducted at prestigious MD Anderson Cancer Center, adding credibility to the research
- Principal investigator to present full results at major industry conference ESTRO 2025
- None.
Insights
Nanobiotix's completed Phase 1 pancreatic cancer study results to be presented at ESTRO 2025, potentially advancing treatment for hard-to-treat disease.
The forthcoming presentation of completed Phase 1 results for JNJ-1900 (NBTXR3) in pancreatic cancer represents a significant clinical development milestone. This study, conducted by MD Anderson Cancer Center, evaluated this nanoparticle-based approach in patients with locally advanced or borderline resectable pancreatic cancer, one of oncology's most challenging indications with historically poor outcomes and limited treatment options.
The completion of both dose escalation and expansion cohorts typically indicates the treatment has demonstrated sufficient safety to establish a recommended Phase 2 dose and potentially shown preliminary signals of activity warranting further investigation. The study design—evaluating the agent after induction chemotherapy and with radiotherapy—aligns with NBTXR3's mechanism of action as a radioenhancer designed to amplify radiation effects within tumor cells.
The selection of this data for presentation at ESTRO, a major radiation oncology conference, suggests the findings merit scientific discussion in the field. While the actual efficacy and safety results remain undisclosed until the May 4th presentation, the fact that Nanobiotix is hosting a follow-up event specifically to discuss these findings indicates potential clinical relevance. For a difficult-to-treat malignancy like pancreatic cancer, even incremental advances in therapeutic approaches could represent meaningful progress.
Nanobiotix's upcoming data presentation for pancreatic cancer therapy signifies pipeline progress with potential partner Johnson & Johnson.
This announcement represents an important developmental milestone for Nanobiotix as they prepare to reveal complete Phase 1 results for their lead technology in pancreatic cancer. The product designation JNJ-1900 (NBTXR3) indicates Johnson & Johnson's involvement with this asset, suggesting the program falls within their previously established collaboration framework.
The pancreatic cancer indication represents a significant market opportunity given the limited effective treatments currently available and poor survival outcomes. For a late-clinical stage biotech company like Nanobiotix, successful demonstration of safety and preliminary efficacy signals in early-phase studies is crucial for validating their proprietary nanoparticle-based technology platform.
The structure of the announcement carries strategic significance. The company has scheduled a dedicated investor event immediately following the scientific presentation, indicating they view these results as potentially material to their business trajectory and investor narrative. The collaboration with MD Anderson Cancer Center adds scientific credibility to their development program.
While this announcement itself doesn't reveal the nature of the results (positive or negative), it establishes a clear timeline for data disclosure that could serve as a potential catalyst. The presentation's acceptance at a major conference like ESTRO suggests the data meets standards for scientific discussion, though the ultimate clinical and commercial significance awaits the full data reveal on May 4th.
- Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CEST
- Nanobiotix will host an event on Monday, May 5th at 8:00 AM EDT / 2:00 PM CEST to review the presented results
PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of full results from the completed dose escalation and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer. The study, conducted by The University of Texas MD Anderson Cancer Center, will be presented by principal investigator Dr. Eugene Koay on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CEST during the 2025 Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO 2025).
PRESENTATION #E25-2265: NANORAY Pancreas: A Phase 1 Study of NBTXR3 (JNJ-1900) Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Cancer (LAPC or BRPC)
Koay EJ, Liu S, Guerrero P, Stokes E, Katz MHG, Ikoma N, Snyder RA, Tzeng CD, Overman MJ, Pant S, Wolff RA, Javle M, Holliday EB, Ludmir EB, Das P, Noticewala S, Koong AC, Tamm EP, Bhutani M
Nanobiotix ConferenceCall
Nanobiotix will host a conference call and webcast featuring Nanobiotix chief executive officer and chairman of the executive board, Laurent Levy, to discuss the data on Monday May 5th, 2025, at 8:00 AM EDT / 2:00 PM CEST.
Details for the call are as follows:
Webcast link: click here
Audio-only dial-in link: click here
Participants can use the audio-only link above to register and obtain dial-in instructions to listen to the presentation via phone and ask questions during the Q&A session, or participants can use the webcast link to register and listen and watch the slide presentation online; the replay version will be available under the same webcast link shortly after the presentation and will be archived on the Company’s website at www.nanobiotix.com. It is recommended to join 10 minutes prior to the event start. Participants are invited to email their questions in advance to investors@nanobiotix.com.
About JNJ-1900 (NBTXR3)
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas for which the product received a European CE mark in 2019. The product candidate’s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.
Radiotherapy-activated NBTXR3 is being evaluated across multiple solid tumor indications as a single agent or in combination with anti-PD-1 immune checkpoint inhibitors, including in NANORAY-312—a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy—the same population being evaluated in the Phase 3 study.
Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating NBTXR3 across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of NBTXR3 with Janssen Pharmaceutica NV, a Johnson & Johnson company.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter
Disclaimer
This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 02, 2025 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2024 universal registration document filed with the AMF on April 02, 2025,, and subsequent filings Nanobiotix makes with the SEC from time to time which are available on the SEC’s website at www.sec.gov. The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.
Contacts
| Nanobiotix | |
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Ricky Bhajun Director, Investor Relations +33 (0)6 42 05 34 15 investors@nanobiotix.com |
| Media Relations | |
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Communications nanobiotixteam@uncappedcommunications.com |
Attachment
FAQ
When will NBTX present Phase 1 pancreatic cancer study results at ESTRO 2025?
What type of pancreatic cancer patients were included in the NBTX Phase 1 study?
How can investors join the NBTX conference call about pancreatic cancer study results?
Who is presenting the NBTX pancreatic cancer study results at ESTRO 2025?
What is the presentation number for NBTX pancreatic cancer study at ESTRO 2025?
